Treatment priorities of children living with asthma are at the core of a special initiative called “Little Airways, Big Voices.”

AAFA partnered with the Allergy & Asthma Network (AAN) ^[3], American Lung Association (ALA), ^[4] and the American Partnership for Eosinophilic Disorders (APFED) ^[5], to create an opportunity for your perspective to inform and shape development of drugs and medical devices designed to treat asthma in children.

As part of the collaboration, we hosted an externally-led patient-focused drug development (PFDD) meeting on September 20, 2021 in the Washington, D.C. area. It provided the asthma community an opportunity to speak directly to Food and Drug Administration (FDA) staff, representatives of pharmaceutical and medical device companies, and other key stakeholders.

The goal of the Little Airways, Big Voices PFDD meeting was to gather patient insights about living with and managing asthma in childhood that will inform new treatment strategies, effectively engage families in drug development, and improve health outcomes.

This initiative was the first of its kind for pediatric asthma. Your voice and perspectives are essential for us to elevate the needs of children and their families managing asthma.